1. Company is a large pharmaceutical bio-manufacturing enterprise in Central China. In the first half of 2008, the company was selected as the national leading enterprise for poverty alleviation, the first "Top 500 Famous Technology Brands in China" and Ling Rui as the "Most Valuable Trademark in China" brand list. Eight products produced by the company entered the medical insurance catalogue, of which the first three varieties were exclusively produced. With the gradual advancement of medical reform, it will help promote the sales of the company's products.

2. The company has been recognized as a high-tech enterprise, and the enterprise income tax has been reduced 15% for three years since 2008. In view of the fact that the income tax rate of the company's main business in 2007 was 33%, this time it was recognized as a high-tech enterprise, which had a great impact on the company's performance.

3. Main financial indicators of the company in the first three quarters of 2009: earnings per share of 0. 1230 (yuan), net assets per share of 2.9 100 (yuan), return on net assets of 4.2400%, and operating income of 3,352,88910.9000 (yuan). The net profit attributable to shareholders of listed companies was 247,538 yuan13.85 yuan, up or down 132+438+04% year-on-year.

4. On May 8, 2009, Ma Yinglong Pharmaceutical Group Co., Ltd. sold 6.636 million shares of unrestricted shares (accounting for 3.3 1% of the company's total share capital) and held 3.4 million shares (accounting for 1.69% of the company's total share capital).